Skip to content
2000
image of The Markers Auxiliary in Distinguishing Between Nodal Nevi and Melanoma Metastases

Abstract

Nodal nevus (NN) and melanoma metastasis (MM) have distinct biological and prognostic significance. They are characterized by different cytomorphological features and varying intranodal localization. However, in some cases, distinguishing them in standard hematoxylin and eosin-stained specimens can be challenging. The aim of this review is to evaluate the usefulness of markers in the diagnosis of NN and MM. The expression of selected markers in NN and MM was examined immunohistochemically in 27 studies. The frequency of HMB-45 and PRAME staining was significantly higher, while p16 was lower in MM than in NN. A slight increase of Ki-67 and decrease of 5-hmC expression in MM compared to NN were also observed. Meanwhile, staining of Melan-A/Mart-1, S-100, and SOX-10 was similar in NN and MM. However, none of the markers applied was completely specific for melanocytes. Although PRAME proved to have the strongest diagnostic potential, it was also detectable in other cell types, especially in lymphocytes and some breast cancers. Immunohistochemical staining of PRAME, HMB-45, and p16 may aid the diagnosis of NN and MM. Ki-67 and 5-hmC may also be of promising significance, whereas the expression of Melan-A/Mart-1, S-100, and SOX-10 does not allow distinguishing NN from MM.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673358592250408170859
2025-06-10
2025-09-11

  • From This Site

    /content/journals/cmc/10.2174/0109298673358592250408170859
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sahin T.K. Rizzo A. Aksoy S. Guven D.C. Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: A systematic review and meta-analysis. Cancers 2024 16 10 1835 10.3390/cancers16101835 38791914
    [Google Scholar]
  2. Garbe C. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. Eur. J. Cancer 2025 215 115152 10.1016/j.ejca.2024.115152 39700658
    [Google Scholar]
  3. Tas F. Erturk K. The course of stage III melanoma in accordance with the severity of node involvement. Curr. Med. Res. Opin. 2019 35 10 1819 1824 10.1080/03007995.2019.1628563 31169423
    [Google Scholar]
  4. Tas F. Erturk K. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma. Int. J. Clin. Oncol. 2019 24 6 721 726 10.1007/s10147‑019‑01410‑4 30788673
    [Google Scholar]
  5. Dumitra T. Faries M.B. Melanoma sentinel lymph node biopsy in the modern era. Surg. Oncol. 2024 57 102162 10.1016/j.suronc.2024.102162 39556928
    [Google Scholar]
  6. Gershenwald J.E. Scolyer R.A. Hess K.R. Sondak V.K. Long G.V. Ross M.I. Lazar A.J. Faries M.B. Kirkwood J.M. McArthur G.A. Haydu L.E. Eggermont A.M.M. Flaherty K.T. Balch C.M. Thompson J.F. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017 67 6 472 492 10.3322/caac.21409 29028110
    [Google Scholar]
  7. Garbe C. Amaral T. Peris K. Hauschild A. Arenberger P. Basset-Seguin N. Bastholt L. Bataille V. Brochez L. del Marmol V. Dréno B. Eggermont A.M.M. Fargnoli M.C. Forsea A.M. Höller C. Kaufmann R. Kelleners-Smeets N. Lallas A. Lebbé C. Leiter U. Longo C. Malvehy J. Moreno-Ramirez D. Nathan P. Pellacani G. Saiag P. Stockfleth E. Stratigos A.J. Van Akkooi A.C.J. Vieira R. Zalaudek I. Lorigan P. Mandala M. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024. Eur. J. Cancer 2025 215 115153 10.1016/j.ejca.2024.115153 39709737
    [Google Scholar]
  8. Hugdahl E. Aziz S. Klingen T.A. Akslen L.A. Prognostic value of immune biomarkers in melanoma loco-regional metastases. PLoS One 2025 20 1 e0315284 10.1371/journal.pone.0315284 39883679
    [Google Scholar]
  9. Rizzo A. Nivolumab plus ipilimumab in melanoma brain metastases. Lancet Oncol. 2022 23 2 e52 10.1016/S1470‑2045(22)00010‑9 35114121
    [Google Scholar]
  10. Guven D.C. Erul E. Kaygusuz Y. Akagunduz B. Kilickap S. De Luca R. Rizzo A. Immune checkpoint inhibitor-related hearing loss: A systematic review and analysis of individual patient data. Support. Care Cancer 2023 31 11 624 10.1007/s00520‑023‑08083‑w 37819422
    [Google Scholar]
  11. Rizzo A. Santoni M. Mollica V. Logullo F. Rosellini M. Marchetti A. Faloppi L. Battelli N. Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: The MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol. 2021 17 12 1455 1466 10.1080/17425255.2021.2029405 35029519
    [Google Scholar]
  12. Rizzo A. Mollica V. Tateo V. Tassinari E. Marchetti A. Rosellini M. De Luca R. Santoni M. Massari F. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: The MOUSEION-05 study. Cancer Immunol. Immunother. 2023 72 6 1381 1394 10.1007/s00262‑023‑03366‑x 36695827
    [Google Scholar]
  13. Carlson J.A. Ross J.S. Slominski A. Linette G. Mysliborski J. Hill J. Mihm M.Jr. Molecular diagnostics in melanoma. J. Am. Acad. Dermatol. 2005 52 5 743 775 10.1016/j.jaad.2004.08.034 15858465
    [Google Scholar]
  14. Blaheta H.J. Sotlar K. Breuninger H. Bueltmann B. Rassner G. Garbe C. Horny H.P. Does intensive histopathological workup by serial sectioning increase the detection of lymph node micrometastasis in patients with primary cutaneous melanoma? Melanoma Res. 2001 11 1 57 63 10.1097/00008390‑200102000‑00007 11254116
    [Google Scholar]
  15. Brennick J.B. Yan S. False-positive cells in sentinel lymph nodes. Semin. Diagn. Pathol. 2008 25 2 116 119 10.1053/j.semdp.2008.03.001 18697715
    [Google Scholar]
  16. Zubovits J. Buzney E. Yu L. Duncan L.M. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum. Pathol. 2004 35 2 217 223 10.1016/j.humpath.2003.09.019 14991540
    [Google Scholar]
  17. Heller R. Becker J. Wasselle J. Baekey P. Cruse C.W. Cox C. King B. Wood H. Reintgen D.S. Detection of occult lymph node metastases in malignant melanoma. Ann. Plast. Surg. 1992 28 1 74 77 10.1097/00000637‑199201000‑00019 1642412
    [Google Scholar]
  18. Satzger I. Völker B. Meier A. Schenck F. Kapp A. Gutzmer R. Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am. J. Surg. Pathol. 2007 31 8 1175 1180 10.1097/PAS.0b013e3180341ebc 17667539
    [Google Scholar]
  19. Jennings C. Kim J. Identification of nodal metastases in melanoma using sox-10. Am. J. Dermatopathol. 2011 33 5 474 482 10.1097/DAD.0b013e3182042893 21552103
    [Google Scholar]
  20. Jungbluth A.A. Serological reagents for the immunohistochemical analysis of melanoma metastases in sentinel lymph nodes. Semin. Diagn. Pathol. 2008 25 2 120 125 10.1053/j.semdp.2008.05.002 18697716
    [Google Scholar]
  21. Orchard G.E. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem. J. 2000 32 8 475 481 10.1023/A:1004192232357 11095072
    [Google Scholar]
  22. Ronchi A. Zito Marino F. Moscarella E. Brancaccio G. Argenziano G. Troiani T. Napolitano S. Franco R. Cozzolino I. PRAME immunocytochemistry for the diagnosis of melanoma metastases in cytological samples. Diagnostics 2022 12 3 646 10.3390/diagnostics12030646 35328198
    [Google Scholar]
  23. Szumera-Ciećkiewicz A. Bosisio F. Teterycz P. Antoranz A. Delogu F. Koljenović S. van de Wiel B.A. Blokx W. van Kempen L.C. Rutkowski P. Christopher van Akkooi A. Cook M. Massi D. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. Eur. J. Cancer 2020 137 175 182 10.1016/j.ejca.2020.06.037 32781392
    [Google Scholar]
  24. Vrotsos E. Alexis J. Can SOX-10 or KBA.62 replace S100 protein in immunohistochemical evaluation of sentinel lymph nodes for metastatic melanoma? Appl. Immunohistochem. Mol. Morphol. 2016 24 1 26 29 10.1097/PAI.0000000000000146 25611246
    [Google Scholar]
  25. Biernacka A. Linos K.D. DeLong P.A. Suriawinata A.A. Padmanabhan V. Liu X. A case of S-100 negative melanoma: A diagnostic pitfall in the workup of a poorly differentiated metastatic tumor of unknown origin. Cytojournal 2016 13 21 10.4103/1742‑6413.190914 27729935
    [Google Scholar]
  26. Riddle N.D. Bui M.M. When melanoma is negative for S100: Diagnostic pitfalls. Arch. Pathol. Lab. Med. 2012 136 3 237 239 10.5858/arpa.2011‑0405‑LE 22372898
    [Google Scholar]
  27. Mohamed A. Gonzalez R.S. Lawson D. Wang J. Cohen C. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl. Immunohistochem. Mol. Morphol. 2013 21 6 506 510 10.1097/PAI.0b013e318279bc0a 23197006
    [Google Scholar]
  28. Gradecki S.E. Slingluff C.L. Jr Gru A.A. PRAME expression in 155 cases of metastatic melanoma. J. Cutan. Pathol. 2021 48 4 479 485 10.1111/cup.13876 32939793
    [Google Scholar]
  29. Lezcano C. Jungbluth A.A. Nehal K.S. Hollmann T.J. Busam K.J. PRAME expression in melanocytic tumors. Am. J. Surg. Pathol. 2018 42 11 1456 1465 10.1097/PAS.0000000000001134 30045064
    [Google Scholar]
  30. Ohsie S.J. Sarantopoulos G.P. Cochran A.J. Binder S.W. Immunohistochemical characteristics of melanoma. J. Cutan. Pathol. 2008 35 5 433 444 10.1111/j.1600‑0560.2007.00891.x 18399807
    [Google Scholar]
  31. Piao Y. Guo M. Gong Y. Diagnostic challenges of metastatic spindle cell melanoma on fine-needle aspiration specimens. Cancer 2008 114 2 94 101 10.1002/cncr.23345 18260089
    [Google Scholar]
  32. Chang O. Argenyi Z. Loss of conventional melanocytic markers in malignant melanoma and lymph node metastasis; an uncommon but dangerous pitfall. Am. J. Dermatopathol. 2017 39 10 760 763 10.1097/DAD.0000000000000737 27759690
    [Google Scholar]
  33. Gao Z. Stanek A. Chen S. A metastatic melanoma with an unusual immunophenotypic profile. Am. J. Dermatopathol. 2007 29 2 169 171 10.1097/DAD.0b013e31802e49a3 17414440
    [Google Scholar]
  34. Steppert C. Krugmann J. Sterlacci W. Simultaneous endocrine expression and loss of melanoma markers in malignant melanoma metastases, a retrospective analysis. Pathol. Oncol. Res. 2020 26 3 1777 1779 10.1007/s12253‑019‑00761‑7 31654227
    [Google Scholar]
  35. Biddle D.A. Evans H.L. Kemp B.L. El-Naggar A.K. Harvell J.D. White W.L. Iskandar S.S. Prieto V.G. Intraparenchymal nevus cell aggregates in lymph nodes: A possible diagnostic pitfall with malignant melanoma and carcinoma. Am. J. Surg. Pathol. 2003 27 5 673 681 10.1097/00000478‑200305000‑00011 12717252
    [Google Scholar]
  36. El Sharouni M.A. Laeijendecker A.E. Suijkerbuijk K.P.M. Witkamp A.J. Sigurdsson V. van Diest P.J. van Gils C.H. Blokx W.A.M. High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. Eur. J. Cancer 2021 149 105 113 10.1016/j.ejca.2021.03.001 33848712
    [Google Scholar]
  37. Holt J.B. Sangueza O.P. Levine E.A. Shen P. Bergman S. Geisinger K.R. Creager A.J. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi. Am. J. Clin. Pathol. 2004 121 1 58 63 10.1309/Y5QAD623MYA21PUY 14750241
    [Google Scholar]
  38. Karimipour D.J. Lowe L. Su L. Hamilton T. Sondak V. Johnson T.M. Fullen D. Standard immunostains for melanoma in sentinel lymph node specimens: Which ones are most useful? J. Am. Acad. Dermatol. 2004 50 5 759 764 10.1016/j.jaad.2003.07.016 15097961
    [Google Scholar]
  39. Lezcano C. Pulitzer M. Moy A.P. Hollmann T.J. Jungbluth A.A. Busam K.J. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am. J. Surg. Pathol. 2020 44 4 503 508 10.1097/PAS.0000000000001393 31633488
    [Google Scholar]
  40. Saab J. Santos-Zabala M.L. Loda M. Stack E.C. Hollmann T.J. Fatty acid synthase and Acetyl-CoA carboxylase are expressed in nodal metastatic melanoma but not in benign intracapsular nodal nevi. Am. J. Dermatopathol. 2018 40 4 259 264 10.1097/DAD.0000000000000939 28654463
    [Google Scholar]
  41. Azzopardi J.G. Ross C.M.D. Frizzera G. Blue naevi of lymph node capsule. Histopathology 1977 1 6 451 461 10.1111/j.1365‑2559.1977.tb01684.x 615846
    [Google Scholar]
  42. Epstein J.I. Erlandson R.A. Rosen P.P. Nodal blue nevi. Am. J. Surg. Pathol. 1984 8 12 907 915 10.1097/00000478‑198412000‑00003 6097130
    [Google Scholar]
  43. Goldman R.L. Blue naevus of lymph node capsule: Report of a unique case. Histopathology 1981 5 4 445 450 10.1111/j.1365‑2559.1981.tb01805.x 7275022
    [Google Scholar]
  44. Lamovec J. Blue nevus of the lymph node capsule. Report of a new case with review of the literature. Am. J. Clin. Pathol. 1984 81 3 367 372 10.1093/ajcp/81.3.367 6322570
    [Google Scholar]
  45. Masci P. Ciardi A. Di Tondo U. Blue nevus of the lymph node capsule. J. Dermatol. Surg. Oncol. 1984 10 8 596 598 10.1111/j.1524‑4725.1984.tb01259.x 6747071
    [Google Scholar]
  46. Kim H.J. Seo J.W. Roh M.S. Lee J.H. Song K.H. Clinical features and prognosis of Asian patients with acral lentiginous melanoma who have nodal nevi in their sentinel lymph node biopsy specimen. J. Am. Acad. Dermatol. 2018 79 4 706 713 10.1016/j.jaad.2018.04.016 29673774
    [Google Scholar]
  47. Ogawa K. Kobayashi N. Miyagawa F. Nakai T. Fukumoto T. Mitsui Y. Arai E. Asada H. Case of nodal nevus with melanocytic cell aggregates in the lymphatic hilum: A potential diagnostic pitfall that requires differentiation from metastatic melanoma of the lymph node. J. Dermatol. 2020 47 6 e242 e244 10.1111/1346‑8138.15325 32201978
    [Google Scholar]
  48. Lee J.J. Granter S.R. Laga A.C. Saavedra A.P. Zhan Q. Guo W. Xu S. Murphy G.F. Lian C.G. 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. Mod. Pathol. 2015 28 2 218 229 10.1038/modpathol.2014.99 25081754
    [Google Scholar]
  49. Dandekar M. Lowe L. Fullen D.R. Johnson T.M. Sabel M.S. Wong S.L. Patel R.M. Discordance in histopathologic evaluation of melanoma sentinel lymph node biopsy with clinical follow-up: Results from a prospectively collected database. Ann. Surg. Oncol. 2014 21 11 3406 3411 10.1245/s10434‑014‑3773‑8 24845727
    [Google Scholar]
  50. Bautista N.C. Cohen S. Anders K.H. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am. J. Clin. Pathol. 1994 102 1 102 108 10.1093/ajcp/102.1.102 8037154
    [Google Scholar]
  51. de Beer F.S.A. van Diest P.J. Sigurdsson V. El Sharouni M. Intra-nodal nevi in sentinel node-negative patients with cutaneous melanoma does not influence survival. J. Eur. Acad. Dermatol. Venereol. 2019 33 12 2291 2295 10.1111/jdv.15814 31318994
    [Google Scholar]
  52. Dohse L. Ferringer T. Nodal blue nevus: a pitfall in lymph node biopsies. J. Cutan. Pathol. 2010 37 1 102 104 10.1111/j.1600‑0560.2009.01304.x 19615001
    [Google Scholar]
  53. Fisher C.J. Hill S. Millis R.R. Benign lymph node inclusions mimicking metastatic carcinoma. J. Clin. Pathol. 1994 47 3 245 247 10.1136/jcp.47.3.245 8163697
    [Google Scholar]
  54. Gambichler T. Scholl L. Stücker M. Bechara F.G. Hoffmann K. Altmeyer P. Othlinghaus N. Clinical characteristics and survival data of melanoma patients with nevus cell aggregates within sentinel lymph nodes. Am. J. Clin. Pathol. 2013 139 5 566 573 10.1309/AJCPG83CMAVFBWLC 23596107
    [Google Scholar]
  55. Kretschmer L. Schnabel V. Kromer C. Bauer-Büntzel C. Richter A. Bremmer F. Kück F. Julius K. Mitteldorf C. Schön M.P. Melanocytic nevi in sentinel lymph nodes: Association with cutaneous nevi and clinical relevance in patients with cutaneous melanomas. J. Cancer Res. Clin. Oncol. 2022 148 11 3125 3134 10.1007/s00432‑021‑03894‑y 35059868
    [Google Scholar]
  56. McCarthy S.W. Palmer A.A. Bale P.M. Hirst E. Naevus cells in lymph nodes. Pathology 1974 6 4 351 358 10.3109/00313027409077346 4449672
    [Google Scholar]
  57. Ricci C. Dika E. Lambertini M. Ambrosi F. Chiarucci F. Chillotti S. Fiorentino M. Fabbri E. Tassone D. Veronesi G. Tartari F. Corti B. The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma. Pathol. Res. Pract. 2022 233 153805 10.1016/j.prp.2022.153805 35361504
    [Google Scholar]
  58. Ridolfi R.L. Rosen P.P. Thaler H. Nevus cell aggregates associated with lymph nodes: Estimated frequency and clinical significance. Cancer 1977 39 1 164 171 10.1002/1097‑0142(197701)39:1<164::AID‑CNCR2820390127>3.0.CO;2‑T 832230
    [Google Scholar]
  59. Smith O.J. Coelho J.A.J. Trevatt A.E. Ross G.L. Clinical significance of intra-nodal naevi in sentinel node biopsies for malignant melanoma. Eur. J. Surg. Oncol. 2016 42 9 1427 1431 10.1016/j.ejso.2016.04.057 27262872
    [Google Scholar]
  60. Subramony C. Lewin J.R. Med M. Nevus cells within lymph nodes. Possible metastases from a benign intradermal nevus. Am. J. Clin. Pathol. 1985 84 2 220 223 10.1093/ajcp/84.2.220 4025228
    [Google Scholar]
  61. Lohmann C.M. Iversen K. Jungbluth A.A. Berwick M. Busam K.J. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma. Am. J. Surg. Pathol. 2002 26 10 1351 1357 10.1097/00000478‑200210000‑00012 12360050
    [Google Scholar]
  62. See S.H.C. Finkelman B.S. Yeldandi A.V. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma. Pathol. Res. Pract. 2020 216 9 153105 10.1016/j.prp.2020.153105 32825968
    [Google Scholar]
  63. Hruban R.H. Eckert F. Baričević B. Melanocytes of a melanocytic nevus in a lymph node from a patient with a primary cutaneous melanoma associated with a small congenital nevus. Am. J. Dermatopathol. 1990 12 4 402 407 10.1097/00000372‑199008000‑00012 2203272
    [Google Scholar]
  64. Bichel P. Ørnsholt J. Benign nevus cells in the lymph nodes. Acta Pathol. Microbiol. Scand. Suppl. 1988 96 1-6 117 122 10.1111/j.1699‑0463.1988.tb05277.x 3345256
    [Google Scholar]
  65. Bowen A.R. Duffy K.L. Clayton F.C. Andtbacka R.H.I. Florell S.R. Benign melanocytic lymph node deposits in the setting of giant congenital melanocytic nevi: The large congenital nodal nevus. J. Cutan. Pathol. 2015 42 11 832 839 10.1111/cup.12580 26268779
    [Google Scholar]
  66. Davis J. Patil J. Aydin N. Mishra A. Misra S. Capsular nevus versus metastatic malignant melanoma – A diagnostic dilemma. Int. J. Surg. Case Rep. 2016 29 20 24 10.1016/j.ijscr.2016.10.040 27810606
    [Google Scholar]
  67. Gonzàlez-Farré M. Ronen S. Keiser E. Prieto V.G. Aung P.P. Three types of nodal melanocytic nevi in sentinel lymph nodes of patients with melanoma: Pitfalls, immunohistochemistry, and a review of the literature. Am. J. Dermatopathol. 2020 42 10 739 744 10.1097/DAD.0000000000001645 32271206
    [Google Scholar]
  68. Hu J. Ren M. Cai X. Zhang Y. Lv J.J. Kong Y.Y. Nevus cell aggregates massively occupying parenchyma of an external iliac lymph node: A case report and review of the literature. J. Cutan. Pathol. 2020 47 12 1175 1180 10.1111/cup.13805 32644206
    [Google Scholar]
  69. Kanner W.A. Barry C.I. Smart C.N. Frishberg D.P. Binder S.W. Wick M.R. Reticulin and NM23 staining in the interpretation of lymph nodal nevus rests. Am. J. Dermatopathol. 2013 35 4 452 457 10.1097/DAD.0b013e318272c104 23694823
    [Google Scholar]
  70. Nonaka D. Chiriboga L. Rubin B.P. Sox10: A pan-schwannian and melanocytic marker. Am. J. Surg. Pathol. 2008 32 9 1291 1298 10.1097/PAS.0b013e3181658c14 18636017
    [Google Scholar]
  71. Piana S. Tagliavini E. Ragazzi M. Zanelli M. Zalaudek I. Ciarrocchi A. Valli R. Lymph node melanocytic nevi: Pathogenesis and differential diagnoses, with special reference to p16 reactivity. Pathol. Res. Pract. 2015 211 5 381 388 10.1016/j.prp.2015.01.003 25661066
    [Google Scholar]
  72. Yan S. Brennick J.B. False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes. Am. J. Surg. Pathol. 2004 28 5 596 600 10.1097/00000478‑200405000‑00005 15105646
    [Google Scholar]
  73. Zengin H.B. Yildiz B. Pukhalskaya T. Smoller B.R. FLI -1/ Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study. J. Cutan. Pathol. 2023 50 3 247 258 10.1111/cup.14373 36454046
    [Google Scholar]
  74. Gambichler T. Sand M. Skrygan M. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res. 2013 23 3 218 220 10.1097/CMR.0b013e32835f9bd4 23458759
    [Google Scholar]
  75. Katarzyna L. Kyriakos O. Linda V. Ingrid S. Petra W. Karin Ö. Evaluation of tubulin β-3 and 5 hydroxy-methyl cytosine as diagnostic and prognostic markers in malignant melanoma. Ann. Diagn. Pathol. 2024 72 152332 10.1016/j.anndiagpath.2024.152332 38776734
    [Google Scholar]
  76. Rawson R.V. Shteinman E.R. Ansar S. Vergara I.A. Thompson J.F. Long G.V. Scolyer R.A. Wilmott J.S. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics. Pathology 2022 54 7 863 873 10.1016/j.pathol.2022.05.012 35987723
    [Google Scholar]
  77. Uchiyama R. Uhara H. Uchiyama A. Ogawa E. Takazawa Y. Ashida A. Koga H. Hayashi K. Kiniwa Y. Okuyama R. 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi. J. Dermatol. Sci. 2014 73 2 161 163 10.1016/j.jdermsci.2013.09.008 24169492
    [Google Scholar]
  78. Kuźbicki Ł. Brożyna A.A. The markers auxiliary in differential diagnosis of early melanomas and benign nevi sharing some similar features potentially leading to misdiagnosis – A review of immunohistochemical studies. Cancer Invest. 2022 40 10 852 867 10.1080/07357907.2022.2134415 36214582
    [Google Scholar]
  79. Bahmad H.F. Oh K.S. Alexis J. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. J. Cutan. Pathol. 2023 50 8 763 772 10.1111/cup.14438 37114299
    [Google Scholar]
  80. Koh S.S. Cassarino D.S. Immunohistochemical expression of p16 in melanocytic lesions: An updated review and meta-analysis. Arch. Pathol. Lab. Med. 2018 142 7 815 828 10.5858/arpa.2017‑0435‑RA 29939777
    [Google Scholar]
  81. Sanki A. Li W. Colman M. Karim R.Z. Thompson J.F. Scolyer R.A. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology 2007 39 6 551 557 10.1080/00313020701684409 18027257
    [Google Scholar]
  82. Beleaua M.A. Jung I. Braicu C. Milutin D. Gurzu S. SOX11, SOX10 and MITF gene interaction: A possible diagnostic tool in malignant melanoma. Life 2021 11 4 281 10.3390/life11040281 33801642
    [Google Scholar]
  83. Ferringer T. Update on immunohistochemistry in melanocytic lesions. Dermatol. Clin. 2012 30 4 567 579, v 10.1016/j.det.2012.06.007 23021046
    [Google Scholar]
  84. Ivan D. Prieto V.G. Use of immunohistochemistry in the diagnosis of melanocytic lesions: Applications and pitfalls. Future Oncol. 2010 6 7 1163 1175 10.2217/fon.10.81 20624128
    [Google Scholar]
  85. Wick M.R. Swanson P.E. Rocamora A. Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J. Cutan. Pathol. 1988 15 4 201 207 10.1111/j.1600‑0560.1988.tb00544.x 3053811
    [Google Scholar]
  86. Orosz Z. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours. Histopathology 1999 34 6 517 525 10.1111/j.1365‑2559.1999.00679.x 10383696
    [Google Scholar]
  87. Prieto V.G. Shea C.R. Use of immunohistochemistry in melanocytic lesions. J. Cutan. Pathol. 2008 35 s2 Suppl. 2 1 10 10.1111/j.1600‑0560.2008.01130.x 18976412
    [Google Scholar]
  88. Prieto V.G. Shea C.R. Immunohistochemistry of melanocytic proliferations. Arch. Pathol. Lab. Med. 2011 135 7 853 859 10.5858/2009‑0717‑RAR.1 21732774
    [Google Scholar]
  89. Chan M.P. Chan M.M. Tahan S.R. Melanocytic nevi in pregnancy: Histologic features and Ki-67 proliferation index. J. Cutan. Pathol. 2010 37 8 843 851 10.1111/j.1600‑0560.2009.01491.x 20015190
    [Google Scholar]
  90. Nasr M.R. El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am. J. Dermatopathol. 2008 30 2 117 122 10.1097/DAD.0b013e3181624054 18360113
    [Google Scholar]
  91. Vyas N.S. Charifa A. Desman G.T. Goldberg M. Singh R. Phelps R.G. McNiff J.M. Observational study examining the diagnostic practice of Ki67 staining for melanocytic lesions. Am. J. Dermatopathol. 2019 41 7 488 491 10.1097/DAD.0000000000001379 31233404
    [Google Scholar]
  92. Fullen D.R. Reed J.A. Finnerty B. McNutt N.S. S100A6 preferentially labels type C nevus cells and nevic corpuscles: Additional support for Schwannian differentiation of intradermal nevi. J. Cutan. Pathol. 2001 28 8 393 399 10.1034/j.1600‑0560.2001.028008393.x 11493376
    [Google Scholar]
  93. Pytlak B. Prochorec-Sobieszek M. Szumera- Ciećkiewicz A. SOX10 as an immunohistochemical marker in cancer diagnostics. Nowotwory. J. Oncol. 2019 69 2 58 64
    [Google Scholar]
  94. Grillini M. Ricci C. Pino V. Pedrini S. Fiorentino M. Corti B. HMB45/PRAME, a novel double staining for the diagnosis of melanocytic neoplasms: Technical aspects, results, and comparison with other commercially available staining (PRAME and Melan A/PRAME). Appl. Immunohistochem. Mol. Morphol. 2022 30 1 14 18 10.1097/PAI.0000000000000972 34508017
    [Google Scholar]
  95. Siref A.B. Huynh C.A.T. Balzer B.L. Frishberg D.P. Essner R. Shon W. Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first-line test for the workup of sentinel lymph node specimen. J. Cutan. Pathol. 2019 46 4 261 266 10.1111/cup.13412 30632191
    [Google Scholar]
  96. Colon Cartagena L. Wang G.Y. Idowu M.O. Smith S.C. Mochel M.C. SOX10-positive perivascular cells in sentinel lymph nodes: A reliably intrinsic internal control. J. Cutan. Pathol. 2020 47 4 415 417 10.1111/cup.13643 31894865
    [Google Scholar]
  97. Willis B.C. Johnson G. Wang J. Cohen C. SOX10: A useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl. Immunohistochem. Mol. Morphol. 2015 23 2 109 112 10.1097/PAI.0000000000000097 25356946
    [Google Scholar]
  98. Blochin E. Nonaka D. Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes. Histopathology 2009 55 5 626 628 10.1111/j.1365‑2559.2009.03415.x 19912373
    [Google Scholar]
  99. Kahn H.J. Marks A. Thom H. Baumal R. Role of antibody to S100 protein in diagnostic pathology. Am. J. Clin. Pathol. 1983 79 3 341 347 10.1093/ajcp/79.3.341 6299096
    [Google Scholar]
  100. Merelo Alcocer V. Flamm A. Chen G. Helm K. SOX10 Immunostaining in granulomatous dermatoses and benign reactive lymph nodes. J. Cutan. Pathol. 2019 46 8 586 590 10.1111/cup.13470 30957251
    [Google Scholar]
  101. Trinidad C.M. Torres-Cabala C.A. Curry J.L. Prieto V.G. Aung P.P. Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. J Clin Pathol 2019 72 4 265 270 10.1136/jclinpath‑2018‑205417 30275100
    [Google Scholar]
  102. Mahmood M.N. Lee M.W. Linden M.D. Nathanson S.D. Hornyak T.J. Zarbo R.J. Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells. Mod. Pathol. 2002 15 12 1288 1293 10.1097/01.MP.0000037313.33138.DF 12481009
    [Google Scholar]
  103. Dwarakanath S. Lee A.K.C. Delellis R.A. Silverman M.L. Frasca L. Wolfe H.J. S-100 protein positivity in breast carcinomas: A potential pitfall in diagnostic immunohistochemistry. Hum. Pathol. 1987 18 11 1144 1148 10.1016/S0046‑8177(87)80382‑9 2824323
    [Google Scholar]
  104. Miettinen M. McCue P.A. Sarlomo-Rikala M. Biernat W. Czapiewski P. Kopczynski J. Thompson L.D. Lasota J. Wang Z. Fetsch J.F. Sox10-a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: A systematic analysis of 5134 tumors. Am. J. Surg. Pathol. 2015 39 6 826 835 10.1097/PAS.0000000000000398 25724000
    [Google Scholar]
  105. Bonetti F. Colombari R. Manfrin E. Zamboni G. Martignoni G. Mombello A. Chilosi M. Breast carcinoma with positive results for melanoma marker (HMB-45). HMB-45 immunoreactivity in normal and neoplastic breast. Am. J. Clin. Pathol. 1989 92 4 491 495 10.1093/ajcp/92.4.491 2552794
    [Google Scholar]
  106. Busam K.J. Jungbluth A.A. Melan-A, a new melanocytic differentiation marker. Adv. Anat. Pathol. 1999 6 1 12 18 10.1097/00125480‑199901000‑00002 10197235
    [Google Scholar]
  107. Cimino-Mathews A. Novel uses of immunohistochemistry in breast pathology: Interpretation and pitfalls. Mod. Pathol. 2021 34 Suppl. 1 62 77 10.1038/s41379‑020‑00697‑3 33110239
    [Google Scholar]
  108. Newman J. Brahmbhatt M. Stoff B.K. Martinez A.P. S-100 protein and SOX10 -positive breast carcinoma mimicking metastatic melanoma. J. Cutan. Pathol. 2020 47 12 1187 1191 10.1111/cup.13822 32710508
    [Google Scholar]
  109. Kriegsmann K. Flechtenmacher C. Heil J. Kriegsmann J. Mechtersheimer G. Aulmann S. Weichert W. Sinn H.P. Kriegsmann M. Immunohistological expression of SOX-10 in triple-negative breast cancer: A descriptive analysis of 113 samples. Int. J. Mol. Sci. 2020 21 17 6407 10.3390/ijms21176407 32899175
    [Google Scholar]
  110. Fliorent R. Benedetto C. Theroux Z. Metastatic triple-negative breast carcinoma mimicking melanoma: A potential diagnostic pitfall. J. Cutan. Pathol. 2024 51 9 654 657 10.1111/cup.14658 38767140
    [Google Scholar]
  111. Curigliano G. Bagnardi V. Ghioni M. Louahed J. Brichard V. Lehmann F.F. Marra A. Trapani D. Criscitiello C. Viale G. Expression of tumor-associated antigens in breast cancer subtypes. Breast 2020 49 202 209 10.1016/j.breast.2019.12.002 31869767
    [Google Scholar]
  112. Tessari A. Pilla L. Silvia D. Duca M. Paolini B. Carcangiu M.L. Mariani L. de Braud F.G. Cresta S. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy? Breast 2018 42 68 73 10.1016/j.breast.2018.08.106 30189381
    [Google Scholar]
  113. Gradecki S.E. Valdes-Rodriguez R. Wick M.R. Gru A.A. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology 2021 78 7 1000 1008 10.1111/his.14312 33280156
    [Google Scholar]
  114. Yates A.J. Banerjee S.S. Bishop P.W. Graham K.E. HMB-45 in non-melanocytic tumours. Histopathology 1993 23 5 477 478 10.1111/j.1365‑2559.1993.tb00499.x 8314224
    [Google Scholar]
  115. Yao D.X. Soslow R.A. Hedvat C.V. Leitao M. Baergen R.N. Melan-A (A103) and inhibin expression in ovarian neoplasms. Appl. Immunohistochem. Mol. Morphol. 2003 11 3 244 249 10.1097/00129039‑200309000‑00007 12966351
    [Google Scholar]
  116. Zuo L. You H. Cai Z. Liao S. Lu X. Li L. Huang W. Melan-A expression in non-melanocytic carcinoma: A potential diagnostic pitfall. Histol. Histopathol. 2023 39 8 1037 1041 10.14670/HH‑18‑696 38205829
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673358592250408170859
Loading
The Markers Auxiliary in Distinguishing Between Nodal Nevi and Melanoma Metastases
Bentham Science Publishers ; https://doi.org/10.2174/0109298673358592250408170859
/content/journals/cmc/10.2174/0109298673358592250408170859
/content/journals/cmc/10.2174/0109298673358592250408170859
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: diagnosis ; melanoma metastasis ; hematoxylin ; marker ; eosin staining ; immunohistochemistry ; Nodal nevus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test